ArticleAmerican journal of respiratory and critical care medicine2023
Improved Survival for Patients with Systemic Sclerosis-associated Pulmonary Arterial Hypertension: The Johns Hopkins Registry.
Open access · greenAbstract read
In one paragraph
Article in American journal of respiratory and critical care medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
5.6field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 39 citations in OpenAlex.
- Phosphodiesterase-5 inhibitors, but not calcium channel blockers, improve peripheral vascular function in systemic sclerosis.Clinical and experimental rheumatology · 2026Article
- Article
- Effectiveness of PAH Specific Treatment Is Comparable Between PAH Associated With Connective Tissue Disease and Idiopathic PAH: Data From the Multicentre National Registry.Pulmonary circulation · 2026Article
- Echocardiographic characterization of combined postcapillary and precapillary pulmonary hypertension in systemic sclerosis with preserved ejection fraction.Echo research and practice · 2026Article
- Treatment of systemic sclerosis-associated pulmonary hypertension with and without interstitial lung disease and its impact on survival: a large cohort study of the German network for systemic sclerosis.Rheumatology (Oxford, England) · 2026Article
- A Novel Computational Pipeline for Acquiring Pressure-Volume Hemodynamics of the Right Ventricle in Pulmonary Hypertension.JACC. Heart failure · 2026Article
- Article
- Refining Risk Prediction in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension.Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography · 2025Article
- A comparative analysis of risk stratification tools in SSc-associated pulmonary arterial hypertension: a EUSTAR analysis.Rheumatology (Oxford, England) · 2025Article
- Bridging knowledge gaps: A case report of pulmonary Veno-occlusive disease in systemic sclerosis.Lung India : official organ of Indian Chest Society · 2025Article
- Outcomes of lung transplantation for scleroderma versus other indications: Insigts from a single center.JHLT open · 2025Article
- Prognostic Value of Echocardiographic Coupling Metrics in Systemic Sclerosis-Associated Pulmonary Vascular Disease.Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography · 2025Article
- Myocardial Disease in Systemic Sclerosis: Recent Updates and Clinical Implications.Current cardiology reports · 2025Review
- Precision Medicine for Pulmonary Vascular Disease: The Future Is Now (2023 Grover Conference Series).Pulmonary circulation · 2025Article
- Impact of Comorbidities on Treatments and Outcomes of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension.Canadian respiratory journal · 2025Article
- Use of artificial intelligence algorithms to analyse systemic sclerosis-interstitial lung disease imaging features.Rheumatology international · 2024Article
- Treatment algorithm for pulmonary arterial hypertension.The European respiratory journal · 2024Review
- Towards a Better Prognosis in Patients with Systemic Sclerosis-Related Pulmonary Arterial Hypertension: Recent Developments and Perspectives.Journal of clinical medicine · 2024Review
- Aberrant long-chain fatty acid metabolism associated with evolving systemic sclerosis-associated pulmonary arterial hypertension.American journal of physiology. Lung cellular and molecular physiology · 2024Observational
- Exercise pulmonary hypertension in patients with systemic sclerosis based on updated guidelines.Scientific reports · 2024Article
Corrections and comments
- Commented on by
Authors and funding
11 authors at 2 institutions in 1 country.
Hussein J HassanDivision of Pulmonary and Critical Care Medicine and.
Mario NaranjoDivision of Pulmonary and Critical Care Medicine and.
Nour AyoubDivision of Pulmonary and Critical Care Medicine and.
Traci HoustenDivision of Pulmonary and Critical Care Medicine and.
Steven HsuDivision of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Aparna BalasubramanianDivision of Pulmonary and Critical Care Medicine and.
Catherine E SimpsonDivision of Pulmonary and Critical Care Medicine and.ORCID 0000-0002-2388-5660
Rachel L DamicoDivision of Pulmonary and Critical Care Medicine and.
Stephen C MathaiDivision of Pulmonary and Critical Care Medicine and.
Todd M KolbDivision of Pulmonary and Critical Care Medicine and.ORCID 0000-0003-0524-7400
Paul M HassounDivision of Pulmonary and Critical Care Medicine and.ORCID 0000-0003-0601-4975
Pulmonary and Critical Care Associates · USJohns Hopkins University · US
Funding
Mechanisms of Right Ventricular Dysfunction in Scleroderma-associated PAHR01HL114910 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI HASSOUN, PAUL M. · 2012 to 2023
$6.2MHopkins Clinical Center for Pulmonary Vascular Disease Phenomics ProgramU01HL125175 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI HASSOUN, PAUL M., MATHAI, STEPHEN C · 2015 to 2019
$1.1MMechanisms and treatment of right ventricular sarcomere dysfunction in scleroderma-associated pulmonary arterial hypertensionK23HL146889 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI HSU, STEVEN · 2019 to 2023
$886kThe role of xanthine oxidoreductase activity and altered metabolism in scleroderma-associated pulmonary arterial hypertensionK23HL153781 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI SIMPSON, CATHERINE · 2020 to 2024
$883kNHLBI NIH HHS K23 HL146889NHLBI NIH HHS K23 HL153781NHLBI NIH HHS R01 HL114910NHLBI NIH HHS U01 HL125175
Abstract
PubMed holds no abstract for this paper.
Indexed as
Hypertension, PulmonaryPulmonary Arterial HypertensionScleroderma, SystemicFamilial Primary Pulmonary HypertensionHumansRegistriespulmonary arterial hypertensionpulmonary hypertensionsystemic sclerosistransplant-free survival
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.